Anti-obesity Drugs Could Be Sold at Much Lower Prices

Change in Cost May Improve Affordability and Access to Treatment

Author: The Obesity Society
Published: 2023/04/14 - Updated: 2023/09/28
Publication Type: Research Study Analysis - Peer-Reviewed: Yes
Contents: Summary - Introduction - Main - Related

Synopsis: Study reveals several anti-obesity medications could be manufactured and profitability sold worldwide at far lower estimated lower prices compared to their high costs. The study highlights the inequality in pricing that exists for effective anti-obesity medications, which are largely unaffordable in most countries, and that these drugs can be produced and sold profitably for low prices. Experts explain that the increasing recognition that diet and exercise alone is unlikely to result in sustained weight loss had led to renewed interest in medication to supplement lifestyle changes.

Introduction

Estimated Minimum Prices and Lowest Available National Prices for Anti-obesity Medications: Improving Affordability and Access to Treatment - Obesity.

New research shows that several anti-obesity medications could be manufactured and profitability sold worldwide at far lower estimated lower prices compared to their high costs, according to a new study in Obesity, The Obesity Society's (TOS) flagship journal.

Main Digest

"Access to medicine is a fundamental element of the human right to health. While the obesity pandemic grows, especially amongst low-income communities, effective medical treatments remain inaccessible for millions in need. Our study highlights the inequality in pricing that exists for effective anti-obesity medications, which are largely unaffordable in most countries. However, we show that these drugs can actually be produced and sold profitably for low prices. A public health approach that prioritizes improving access to medications should be adopted, instead of allowing companies to maximize profits," said Jacob Levi, Intensive Care Medicine, Royal Free Hospital NHS Trust, London, United Kingdom. Levi is the corresponding author of the study.

Experts explain that the increasing recognition that diet and exercise alone is unlikely to result in sustained weight loss had led to renewed interest in medication to supplement lifestyle changes. Randomized controlled trials have demonstrated positive results with oral and injectable medications. However, these medications remain prohibitively expensive in most countries. Such high prices make it challenging for millions of people to afford the medications and obtain access to treatment.

"It would be great if everyone had affordable access to all medicines that might improve their health. Yet that is simply not possible, nor will it ever be. What is truly needed is a better way to ration the health care dollars currently available in efforts to maximize population health. That is the challenge ahead not just for anti-obesity medications but for all treatments," said Eric A. Finkelstein, professor, Duke-NUS Medical School, Singapore, in a commentary about the study.

On the other hand, the authors have called for a public health based approach to obesity management similar to that used with other diseases. Andrew Hill, Department of Pharmacology and Therapeutics, University of Liverpool, United Kingdom, supervising author of the study, commented:

"Worldwide, more people are dying from diabetes and clinical obesity than HIV, tuberculosis and malaria combined now. Millions of lives have been saved by treating infectious diseases at low cost in poor countries. Now we need to repeat this medical success story, with mass treatment of diabetes and clinical obesity at low prices. Pharmaceutical companies have an ethical responsibility to make their new treatments for diabetes and obesity available for anyone in need, in any country."

The study's authors searched national drug price databases and collected information on six medications:

Across a range of 16 low, middle and high-income countries. In each country, researchers assessed multiple online national price databases and selected the lowest available price from each of the sources. Medications selected were chosen because they are proven effective and because they illustrate a range of different monotherapies, combination tablets and injectable treatments.

Estimated minimum prices (EMPs) for anti-obesity medications were calculated using established methodology using active pharmaceutical ingredients from the Panjiva database. EMPs were calculated per 30-day course and include costs of active pharmaceutical ingredients, excipients, formulation, taxation and 10% profit margin.

Results revealed that national prices of oral and injectable anti-obesity medications were significantly higher than calculated EMPs.

Oral Medications

Injectable Medications

The study's authors note that EMPs are meant as realistic targets for competitive generic production rather than patented versions. Caroline M. Apovian, MD, FTOS, co-director, Center for Weight Management and Wellness and professor of medicine at Harvard Medical School in Boston, Mass., commented:

"Once we have shown that anti-obesity agents notably GLP-1 and combinations thereof lower cardiovascular risk, we can then demand universal insurance coverage of these agents. These agents used for obesity prior to the advent of type 2 diabetes, cardiovascular disease and other complications, have the power to reduce the cardiovascular burden and lower mortality worldwide."

Apovian was not associated with the research.

Other Authors of the Study Include:

Junzheng Wang, Medical Sciences Office, Oxford University, Clinical Academic Graduate School, University of Oxford, Oxford, United Kingdom and Francois Venter, Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Support Disclosure:

Venter has received support from the Bill and Melinda Gates Foundation, U.S. Agency for International Development, Uni-taid, SA Medical Research Council, Foundation for Innovative New Diagnostics, the Children's Investment Fund Foundation, Gilead, ViiV, Mylan, Merck, Adcock-Ingram, Aspen, Abbott, Roche, Johnson & Johnson, Sanofi, Virology Education, SA HIV Clinicians Society and Dira Sengwe. The other authors declared no conflict of interest.

Funding Disclosure:

Funding for this study was provided by the Make Medicines Affordable/International Treatment Preparedness Coalition, grant number ITPC-MV_2020, and National Heart, Lung, and Blood Institute of the National Institutes of Health under award number UG3HL156388.

The study, titled "Estimated Minimum Prices and Lowest Available National Prices for Anti-obesity Medications: Improving Affordability and Access to Treatment," published in the print issue of Obesity May 2023.

Attribution/Source(s):

This peer reviewed publication titled Anti-obesity Drugs Could Be Sold at Much Lower Prices was selected for publishing by Disabled World's editors due to its relevance to the disability community. While the content may have been edited for style, clarity, or brevity, it was originally authored by The Obesity Society and published 2023/04/14 (Edit Update: 2023/09/28). For further details or clarifications, you can contact The Obesity Society directly at obesity.org Disabled World does not provide any warranties or endorsements related to this article.

Related Publications

Share This Information To:
𝕏.com Facebook Reddit

Page Information, Citing and Disclaimer

Disabled World is an independent disability community founded in 2004 to provide news and information to people with disabilities, seniors, their family and carers. We'd love for you to follow and connect with us on social media!

Cite This Page (APA): The Obesity Society. (2023, April 14 - Last revised: 2023, September 28). Anti-obesity Drugs Could Be Sold at Much Lower Prices. Disabled World. Retrieved June 13, 2024 from www.disabled-world.com/medical/pharmaceutical/anti-obesity-meds.php

Permalink: <a href="https://www.disabled-world.com/medical/pharmaceutical/anti-obesity-meds.php">Anti-obesity Drugs Could Be Sold at Much Lower Prices</a>: Study reveals several anti-obesity medications could be manufactured and profitability sold worldwide at far lower estimated lower prices compared to their high costs.

Disabled World provides general information only. Materials presented are never meant to substitute for qualified medical care. Any 3rd party offering or advertising does not constitute an endorsement.